Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVS NYSE:CATX NASDAQ:HSAQ NASDAQ:MZOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$6.26-3.5%$6.69$6.02▼$14.38$514.22M0.84430,112 shs391,050 shsCATXPerspective Therapeutics$4.20+1.7%$3.25$1.60▼$16.55$306.56M1.181.09 million shs924,507 shsHSAQHealth Sciences Acquisitions Co. 2$2.92-3.6%$2.98$9.41▼$13.80$32.74M0.09205,918 shs91,794 shsMZORMazor Robotics$58.23$58.23$41.60▼$76.56$1.53B1.39292,420 shs37 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus-3.54%-10.19%-2.64%-19.95%-12.57%CATXPerspective Therapeutics+1.69%+5.53%+21.74%+116.49%-64.88%HSAQHealth Sciences Acquisitions Co. 20.00%-2.67%-13.10%+2.46%-66.20%MZORMazor Robotics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBVSBioventus2.7717 of 5 stars3.40.00.00.01.13.31.3CATXPerspective Therapeutics2.3686 of 5 stars4.61.00.00.02.00.80.0HSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/AN/AN/AN/AMZORMazor RoboticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.75Moderate Buy$13.75119.65% UpsideCATXPerspective Therapeutics 3.18Buy$12.56198.94% UpsideHSAQHealth Sciences Acquisitions Co. 2 0.00N/AN/AN/AMZORMazor Robotics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MZOR, BVS, CATX, and HSAQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$12.006/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.006/3/2025CATXPerspective TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.005/14/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/13/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.005/7/2025BVSBioventusCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$15.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$567.70M0.91$0.50 per share12.58$2.80 per share2.24CATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/AHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/A($0.62) per shareN/AMZORMazor Robotics$64.95M23.61N/AN/A$4.46 per share13.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23M-$0.48N/A13.61N/A-7.11%15.61%4.01%N/ACATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/13/2025 (Estimated)HSAQHealth Sciences Acquisitions Co. 2-$380KN/A0.00∞N/AN/AN/A-2.38%N/AMZORMazor Robotics-$12.41M-$0.50N/A342.53N/A-37.29%-7.70%-6.64%N/ALatest MZOR, BVS, CATX, and HSAQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025N/ACATXPerspective Therapeutics-$0.30N/AN/AN/A$0.17 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/AHSAQHealth Sciences Acquisitions Co. 2N/AN/AN/AN/AN/AMZORMazor RoboticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99CATXPerspective TherapeuticsN/A9.609.60HSAQHealth Sciences Acquisitions Co. 2N/A0.170.61MZORMazor RoboticsN/A5.495.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%CATXPerspective Therapeutics54.66%HSAQHealth Sciences Acquisitions Co. 289.71%MZORMazor Robotics32.68%Insider OwnershipCompanyInsider OwnershipBVSBioventus33.00%CATXPerspective Therapeutics3.72%HSAQHealth Sciences Acquisitions Co. 221.90%MZORMazor RoboticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.14 million54.46 millionNot OptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableHSAQHealth Sciences Acquisitions Co. 2411.21 million8.76 millionNot OptionableMZORMazor RoboticsN/A26.33 millionN/AOptionableMZOR, BVS, CATX, and HSAQ HeadlinesRecent News About These CompaniesUAMS reaches 500 robotic spine surgeriesMarch 6, 2025 | beckersspine.comBSpine, orthopedic robotic milestones in 45 daysFebruary 21, 2025 | beckersspine.comBDr. Andrew Chung performs 1st dualLIF endoscopic spine case with Medtronic robotFebruary 19, 2025 | beckersspine.comBForSight Robotics adds Fred Moll to board, hires R&D VP from MedtronicFebruary 14, 2025 | massdevice.com4 robotic surgery trends to watch in 2025January 29, 2025 | medtechdive.comMBest cheap robot vacuums in 2024October 30, 2024 | tomsguide.comTTop 4 robot vacuums for small spaces to shop on October Prime DayOctober 7, 2024 | mashable.comMThe top 4 robot vacuums for carpet to look for on October Prime DayOctober 6, 2024 | mashable.comMRobot vacuum cleaners to avoid buyingSeptember 29, 2024 | choice.com.auCNew AI-Powered Robot Specializes In Picking Citrus FruitSeptember 17, 2024 | nocamels.comNMedtronic's spine robot: 5 things to knowSeptember 9, 2024 | beckersspine.comBThe Best Cheap Robot Vacuums for 2024August 13, 2024 | pcmag.comPOpenAI-backed startup Figure teases new humanoid robot ‘Figure 02’August 4, 2024 | venturebeat.comVBest Robotic Lawn MowersMay 18, 2024 | consumerreports.orgCrobot failMay 18, 2024 | hackaday.comHCould a robot care for grandma?May 8, 2024 | nationalgeographic.comNFormer Mazor Robotics VP Guilty of Insider TradingMay 2, 2024 | ryortho.comRThe best robot vacuum deals this week include the Roomba j7 (still) at 50% offApril 5, 2024 | mashable.comMRobotic technology revolutionizing functions at Winchester Medical CenterMarch 28, 2024 | winchesterstar.comWMECH.5300 Autonomous Robotic Systems (Formerly 22.530)March 19, 2024 | uml.eduUNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMZOR, BVS, CATX, and HSAQ Company DescriptionsBioventus NYSE:BVS$6.26 -0.23 (-3.54%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$6.26 +0.00 (+0.08%) As of 07/18/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Perspective Therapeutics NYSE:CATX$4.20 +0.07 (+1.69%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$4.22 +0.02 (+0.48%) As of 07/18/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ$2.92 -0.11 (-3.63%) As of 07/15/2025Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.Mazor Robotics NASDAQ:MZORMazor Robotics Ltd., together with its subsidiaries, engages in the development, production, and marketing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the United States and internationally. It operates in the field of computer assisted surgery that enable the use of surgical instruments with high precision and minimal invasiveness and that simplifies complex surgical procedures. The company's surgical robotic-guidance systems and complementary products are used to conduct spine and brain procedures in an accurate and secure manner. It also offers Mazor X, a renaissance system and its accessories are used in spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision, and cement augmentations. The company was formerly known as Mazor Surgical Technologies Ltd. and changed its name to Mazor Robotics Ltd. in 2010. Mazor Robotics Ltd. was founded in 2000 and is based in Caesarea, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
